Cargando…
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
BACKGROUND AND AIM: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS: The retrospective study included COVID-19 patients with C-reactiv...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137353/ https://www.ncbi.nlm.nih.gov/pubmed/34023513 http://dx.doi.org/10.1016/j.pupt.2021.102039 |